— Know what they know.
Not Investment Advice

MBX NASDAQ

MBX Biosciences, Inc. Common Stock
1W: -10.1% 1M: -5.3% 3M: -8.6% YTD: +4.1% 1Y: +157.2%
$31.85
+0.06 (+0.19%)
 
Weekly Expected Move ±14.3%
$23 $28 $32 $37 $42
NASDAQ · Healthcare · Biotechnology · Alpha Radar Neutral · Power 41 · $1.1B mcap · 15M float · 3.97% daily turnover · Short 84% of daily vol

Balance Sheet Trends

Total Assets
$385M +43.4% ▲
3Y CAGR: +104.4%
Total Liabilities
$16M +43.5% ▲
3Y CAGR: -43.4%
Shareholders Equity
$369M +43.4% ▲
Cash & Investments
$374M +42.6% ▲
3Y CAGR: +106.5%
Total Debt
$596K +248.5% ▲
3Y CAGR: +8.9%
Net Debt
-$75M -51.9% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2022FY2023FY2024FY2025
— Assets —
Cash$24M$31M$49M$75M
Short-Term Investments$18M$50M$213M$298M
Cash & ST Investments$42M$81M$262M$374M
Net Receivables$142K$208K$682K$2M
Inventory$0$0$0$0
Other Current Assets$84K$133K$803K$6M
Total Current Assets$44M$83M$267M$382M
Property, Plant & Equip.$842K$665K$1M$3M
Goodwill & Intangibles$0$0$0$0
Long-Term Investments$0$0$0$0
Other Non-Current Assets$42K$50K$50K$383K
Total Non-Current Assets$884K$715K$1M$4M
Total Assets$45M$84M$269M$385M
— Liabilities —
Accounts Payable$976K$1M$5M$3M
Short-Term Debt$0$0$0$172K
Deferred Revenue$0$0$0$0
Other Current Liabilities$1M$1M$2M$12M
Total Current Liabilities$3M$4M$11M$15M
Long-Term Debt$0$0$0$424K
Other Non-Current Liab.$84M$153M$42K$2K
Total Non-Current Liabilities$84M$153M$42K$426K
Total Liabilities$88M$157M$11M$16M
— Equity —
Common Stock$1K$1K$5K$6K
Retained Earnings-$43M-$76M-$138M-$224M
Accumulated OCI$3K$60K$55K$286K
Total Stockholders Equity-$43M-$72M$257M$369M
Total Liabilities & Equity$45M$84M$269M$385M
— Key Metrics —
Total Debt$461K$324K$171K$596K
Net Debt-$24M-$30M-$49M-$75M
Total Investments$18M$50M$213M$298M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms